Real-world Effectiveness of Combination Therapy in Asthma

CompletedOBSERVATIONAL
Enrollment

815,377

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

June 30, 2007

Study Completion Date

February 28, 2010

Conditions
Asthma
Interventions
DRUG

Fluticasone / formoterol metered dose inhaler

Prescribed at the same BDP-equivalent dose as baseline ICS

DRUG

Fluticasone / salmeterol dry powder inhaler

Prescribed at the same BDP-equivalent dose as baseline ICS

DRUG

Budesonide / formoterol dry powder inhaler

Prescribed at the same BDP-equivalent dose as baseline ICS

DRUG

Fluticasone / salmeterol dry powder inhaler

Prescribed at ≥twice BDP-equivalent dose as baseline ICS

DRUG

Fluticasone / salmeterol metred dose inhaler

Prescribed at ≥twice BDP-equivalent dose as baseline ICS

DRUG

BUD/FOR dry powder inhaler

Prescribed at ≥twice BDP-equivalent dose as baseline ICS

Trial Locations (1)

SW8 5NQ

General Practice Research Database, London

All Listed Sponsors
collaborator

Mundipharma Research Limited

INDUSTRY

lead

Research in Real-Life Ltd

NETWORK

NCT01141465 - Real-world Effectiveness of Combination Therapy in Asthma | Biotech Hunter | Biotech Hunter